Comparative real-world outcomes with talquetamab and teclistamab in relapsed/refractory multiple myeloma: A TriNetX observational study.

作者
Aneeq Mahmood Khan,Rubia Ali,Anitha Sangem,Zainab Rahim,Rauf Niazi,Neel Ketankumar Parikh,Zim Warda Hasan
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:44 (16_suppl) 被引量:1
标识
DOI:10.1200/jco.2026.44.16_suppl.e19519
摘要

e19519 Background: Talquetamab (GPRC5D) and teclistamab (BCMA) are bispecific antibodies for relapsed/refractory multiple myeloma (RRMM), but comparative real-world evidence is limited. We compared 1-year effectiveness and safety outcomes between talquetamab and teclistamab. Methods: We conducted a retrospective cohort study in the TriNetX US Collaborative Network. Adults (≥18 years) with RRMM treated with talquetamab or teclistamab from October 2022–November 2025 were included. Patients with solitary plasmacytoma, plasma cell leukemia, or clinical trial–only monitoring codes were excluded. Cohorts were propensity score matched 1:1 on demographics and comorbidities (198 per group). Outcomes through 365 days post-index included all-cause mortality, remission, immune/hematologic toxicities, infections, and organ complications. Effect estimates included risk difference (RD), risk ratio (RR), hazard ratio (HR), 95% confidence intervals (CI), and log-rank p values. Results: Among 1,626 eligible RRMM patients, 402 received talquetamab and 1,224 received teclistamab prior to matching. After matching, baseline characteristics were balanced (mean age 66.8 years; 42% female; similar comorbidity profiles). Grade 3 neutropenia was more common with talquetamab (25.8%) than teclistamab (19.7%) (RD 0.061, 95% CI −0.014 to 0.136; RR 1.31, 95% CI 0.96–1.79; HR 1.46, 95% CI 0.99–2.15; log-rank p=0.054). Grade 3 lymphopenia incidence was similar (5.6% vs 5.1%) (RD 0.005, 95% CI −0.034 to 0.044; RR 1.10, 95% CI 0.55–2.20; HR 1.28, 95% CI 0.63–2.61; log-rank p=0.49). Acute kidney injury was numerically higher with teclistamab (29.3% vs 22.2%) (RD −0.071, 95% CI −0.154 to 0.012; RR 0.76, 95% CI 0.56–1.04; HR 0.77, 95% CI 0.54–1.10; log-rank p=0.15). Mortality (18.2% vs 20.7%; HR 0.91; log-rank p=0.61) and remission (29.1% vs 31.6%; HR 0.95; log-rank p=0.74) were similar between talquetamab and teclistamab. Cytokine release syndrome occurred more often with talquetamab (20.2% vs 14.6%; HR 1.49; log-rank p=0.17). Neurotoxicity was comparable (9.6% vs 7.9%; HR 1.24; log-rank p=0.52). Pneumonia (16.2% vs 20.3%) and sepsis (10.6% vs 13.1%) were numerically lower with talquetamab; thrombocytopenia and hepatotoxicity were similar. Conclusions: In this real-world propensity-matched RRMM cohort, talquetamab and teclistamab had comparable 1-year mortality and remission, with differing toxicity profiles. Talquetamab was associated with higher grade 3 neutropenia and numerically higher cytokine release syndrome, whereas teclistamab showed a signal toward more acute kidney injury and higher infection rates. These data may support individualized treatment selection based on toxicity risk.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
zi完成签到,获得积分20
刚刚
1秒前
1秒前
1秒前
所所的应助被大胆的自行车采纳,获得10
2秒前
3秒前
香蕉觅云的应助被mof采纳,获得10
4秒前
海绵宝宝完成签到 ,获得积分10
5秒前
5秒前
5秒前
初初初啊发布了新的文献求助10
5秒前
科研通AI2S的应助被科研通管家采纳,获得10
5秒前
DW的应助被科研通管家采纳,获得10
6秒前
深情安青的应助被科研通管家采纳,获得10
6秒前
科研通AI2S的应助被密苏里采纳,获得10
6秒前
6秒前
风吹麦浪的应助被科研通管家采纳,获得10
6秒前
Owen的应助被科研通管家采纳,获得10
6秒前
苏莱曼完成签到,获得积分10
6秒前
丘比特的应助被科研通管家采纳,获得10
6秒前
无花果的应助被科研通管家采纳,获得10
6秒前
Hello的应助被科研通管家采纳,获得10
6秒前
无极微光的应助被科研通管家采纳,获得20
7秒前
7秒前
雯雯少完成签到,获得积分10
7秒前
无花果的应助被科研通管家采纳,获得10
7秒前
无极微光的应助被科研通管家采纳,获得20
7秒前
7秒前
共享精神的应助被科研通管家采纳,获得10
7秒前
renn发布了新的文献求助20
7秒前
今后的应助被科研通管家采纳,获得10
7秒前
7秒前
CipherSage的应助被科研通管家采纳,获得10
7秒前
7秒前
Jun的应助被科研通管家采纳,获得10
8秒前
寒冷紫青的应助被清辉影采纳,获得80
8秒前
8秒前
Shu发布了新的文献求助10
9秒前
蟹lao板板完成签到,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183923
求助须知:如何正确求助?哪些是违规求助? 9573132
关于积分的说明 21829461
捐赠科研通 7781024
什么是DOI,文献DOI怎么找? 3434150
关于科研通互助平台的介绍 2558333
邀请新用户注册赠送积分活动 2480648